236 related articles for article (PubMed ID: 26670587)
21. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Krempien R; Muenter MW; Huber PE; Nill S; Friess H; Timke C; Didinger B; Buechler P; Heeger S; Herfarth KK; Abdollahi A; Buchler MW; Debus J
BMC Cancer; 2005 Oct; 5():131. PubMed ID: 16219105
[TBL] [Abstract][Full Text] [Related]
23. Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer.
Atasoy BM; Dane F; Uçüncü Kefelı A; Cağlar H; Cıngı A; Turhal NS; Abacioğlu U; Yeğen C
Turk J Gastroenterol; 2011 Feb; 22(1):60-4. PubMed ID: 21480113
[TBL] [Abstract][Full Text] [Related]
24. Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Brunner TB; Tinkl D; Grabenbauer GG; Meyer T; Brueckl WM; Sauer R
Strahlenther Onkol; 2006 Apr; 182(4):210-5. PubMed ID: 16622622
[TBL] [Abstract][Full Text] [Related]
25. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V
JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.
Kullmann F; Hollerbach S; Dollinger MM; Harder J; Fuchs M; Messmann H; Trojan J; Gäbele E; Hinke A; Hollerbach C; Endlicher E
Br J Cancer; 2009 Apr; 100(7):1032-6. PubMed ID: 19293797
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.
Maurel J; Martin-Richard M; Conill C; Sánchez M; Petriz L; Ginès A; Miquel R; Gallego R; Cajal R; Ayuso C; Navarro S; Marmol M; Nadal C; Augé JM; Fernández-Cruz L; Gascón P
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1391-8. PubMed ID: 16965868
[TBL] [Abstract][Full Text] [Related]
28. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Assenat E; Azria D; Mollevi C; Guimbaud R; Tubiana-Mathieu N; Smith D; Delord JP; Samalin E; Portales F; Larbouret C; Robert B; Bibeau F; Bleuse JP; Crapez E; Ychou M; Pèlegrin A
Oncotarget; 2015 May; 6(14):12796-808. PubMed ID: 25918250
[TBL] [Abstract][Full Text] [Related]
29. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.
Wilkowski R; Boeck S; Ostermaier S; Sauer R; Herbst M; Fietkau R; Flentje M; Miethe S; Boettcher HD; Scholten T; Bruns CJ; Rau HG; Hinke A; Heinemann V
Br J Cancer; 2009 Dec; 101(11):1853-9. PubMed ID: 19904268
[TBL] [Abstract][Full Text] [Related]
30. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma.
Pipas JM; Zaki BI; McGowan MM; Tsapakos MJ; Ripple GH; Suriawinata AA; Tsongalis GJ; Colacchio TA; Gordon SR; Sutton JE; Srivastava A; Smith KD; Gardner TB; Korc M; Davis TH; Preis M; Tarczewski SM; MacKenzie TA; Barth RJ
Ann Oncol; 2012 Nov; 23(11):2820-2827. PubMed ID: 22571859
[TBL] [Abstract][Full Text] [Related]
32. Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose.
Wilkowski R; Thoma M; Weingandt H; Dühmke E; Heinemann V
JOP; 2005 May; 6(3):216-30. PubMed ID: 15883472
[TBL] [Abstract][Full Text] [Related]
33. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.
Shinoto M; Yamada S; Terashima K; Yasuda S; Shioyama Y; Honda H; Kamada T; Tsujii H; Saisho H;
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):498-504. PubMed ID: 26883565
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
Habermehl D; Kessel K; Welzel T; Hof H; Abdollahi A; Bergmann F; Rieken S; Weitz J; Werner J; Schirmacher P; Büchler MW; Debus J; Combs SE
Radiat Oncol; 2012 Mar; 7():28. PubMed ID: 22385572
[TBL] [Abstract][Full Text] [Related]
35. Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer.
Igarashi H; Ito T; Kawabe K; Hisano T; Arita Y; Kaku T; Takayanagi R
World J Gastroenterol; 2008 Sep; 14(34):5311-5. PubMed ID: 18785284
[TBL] [Abstract][Full Text] [Related]
36. Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer.
van Zweeden AA; van der Vliet HJ; Wilmink JW; Meijerink MR; Meijer OW; Bruynzeel AM; van Tienhoven G; Giovannetti E; Kazemier G; Jacobs MA; Verheul HM
Clin Cancer Res; 2015 Oct; 21(20):4569-75. PubMed ID: 26056353
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733
[TBL] [Abstract][Full Text] [Related]
38. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
[TBL] [Abstract][Full Text] [Related]
39. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
40. [Three-dimensional conformal radiation therapy concurrent with full dose Gemcitabine for locally advanced inoperable pancreatic cancer].
Mendlovic S; Symon Z; Kundel Y; Rabin T; Catane R; Pfeffer R
Harefuah; 2008 May; 147(5):384-7, 480. PubMed ID: 18770957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
